Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 157 participants.
Also called NCT05475665
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 157 participants
- Sponsor
- Registry
-
NCT05475665
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05475665. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-14 (actual); primary completion 2023-03-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
- Condition
- Essential Hypertension
- Intervention (Drug)
- Irbesartan/Amlodipine
- Intervention (Drug)
- Irbesartan
- Lead sponsor
- Handok Inc.
Record details
- Record id
cardio:ct-nct05475665- Content hash
3f16b85749952bffabdaecbb48421d9e5fbb7afe38685cf8fb6afe1f01d62fd0